Medical Network News on August 6th: Xinjiang Tefeng Pharmaceutical Co., Ltd. has received CDE acceptance for its application for the market of calcitriol oral solution submitted for imitation of Category 3, which is the first in the world. According to data from Menet.com, the terminal calcitriol market in China's public medical institutions and Chinese urban physical pharmacies will exceed 2.5 billion yuan in 2020. The drug has not yet been approved for oral liquid formulations in the world.

Calcitriol is one of the active metabolic products of vitamin D3. It has a critical role in regulating the body's calcium balance. It can be clinically used for postmenopausal bone looseness, postoperative parathyroid hypofunction, vitamin D-dependent rickets, etc.

The secondary forms of calcitriol currently on the market today include capsules, soft capsules, ointments, etc., and no oral liquid preparation has been approved yet. According to data from Menet.com, the market size of calcitriol in China’s urban public hospitals, county-level public hospitals, urban communities, and prefecture health centers (referred to as Chinese public medical institutions) and physical pharmacies in cities in China will exceed 2.5 billion yuan in 2020, a year-on-year increase. An increase of about 5.9%.

At present, only one company from Xinjiang Tefeng Pharmaceutical has submitted an application for the market of calcitriol oral solution, and it is hopeless to become the first imitation type (the first imitation of the dosage form).

Affected by the epidemic, the market size of terminal vitamin products in China's public medical institutions will decline in 2020, and calcitriol is at the top of the list of generic drugs in this subcategory; the market size of terminal vitamin products in Chinese urban physical pharmacies contravenes the trend With an increase of 15%, the dominance of vitamin D is hard to shake.

　　2020年中国城市实体药店终端维生素类TOP10产物

　　起源：米内网中国城市实体药店终端竞争格式

Among the TOP10 products of terminal vitamins in Chinese urban physical pharmacies in 2020, vitamin D drops have a sales volume of more than 2 billion, and vitamin AD drops are sprinting to the 1 billion mark; sales of multiple products have shown Growth trend, among which vitamin C effervescent tablets and vitamin C taste tablets both rose by more than 60%.

  From the perspective of the competition format of vitamin product manufacturers, Qingdao Shuangjing Pharmaceutical ranks among the "big brothers" with vitamin D drops, accounting for nearly 30% of the market share, followed by Bayer, and Wyeth ranks third.